Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Client Area Book a 7-day Readout
Edge Therapeutics, Inc. logo — Pioneering novel therapies to dramatically improve outcomes...

Edge Therapeutics, Inc.

Pioneering novel therapies to dramatically improve outcomes for life-threatening neurological conditions.

Founded 2009 United States United States 4 employees Series C Total: $101.47M Biotechnology, Health Care

General Information

Company Name Edge Therapeutics, Inc.
Founded Year 2009
Location United States United States
Founders / Decision Makers
Team member
Employees 4
Industries Biotechnology, Health Care
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Edge Therapeutics, Inc.. To contact Edge Therapeutics, Inc., visit edgetherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Edge Therapeutics, Inc. compare?

A PDF of Edge Therapeutics, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Edge Therapeutics, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Edge Therapeutics, Inc.

Edge Therapeutics is a **clinical-stage biotechnology company** founded in **2009** and based in Berkeley Heights, New Jersey. The company's slogan, "Pioneering novel therapies to dramatically improve outcomes for life-threatening neurological conditions," reflects its focus on creating and bringing to market innovative therapies for acute, life-threatening neurological conditions in hospital settings. Their lead product candidate, **EG-1962**, aims to significantly enhance patient outcomes and alter the treatment approach for aneurysmal subarachnoid hemorrhage (aSAH), while their second product candidate, **EG-1964**, is under evaluation as a preventive treatment for chronic subdural hematoma. The company successfully raised a significant **$56.00M Series C investment** on **09 April 2015** from a notable group of investors including **New Leaf Venture Partners, Venrock, Sofinnova Investments, Franklin Advisors, BioMed Ventures, and Janus Capital Group**. With its strategic focus on developing therapies for critical neurological conditions and a strong backing from prominent investors, Edge Therapeutics is positioned to make significant contributions to the biotechnology and healthcare industries.

Business keywords: clinical-stage, neurological conditions, therapy, acute treatment, EG-1962, aneurysmal subarachnoid hemorrhage, EG-1964, chronic subdural hematoma, hospital-based therapies, patient outcomes, Berkeley Heights, New Jersey, innovation, life-threatening

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $56.00M 6
New Leaf Venture Partners Venrock Sofinnova Investments
New Leaf Venture Partners, Venrock +4
09 Apr 2015
Series C $16.50M -
01 Dec 2014
Debt Financing $10.00M 1
Hercules Capital
Hercules Capital
08 Sep 2014
Series C $18.00M 1
Maxim Group LLC
Maxim Group LLC
04 Jun 2013
Seed Round $118.50K -
17 Sep 2012
Seed Round $219.50K -
24 Jun 2011
Seed Round Undisclosed 1
Hatzimemos / Libby
Hatzimemos / Libby
01 Jan 2011
Seed Round $634.50K -
08 Nov 2010
Seed Round Undisclosed 1
NJEDA
NJEDA
03 May 2010

Edge Therapeutics, Inc. Alternatives & Competitors

View All Alternatives
Edge Therapeutics, Inc. vs
Affymax
Affymax

Pioneering innovative therapies for life-threatening conditions, aiming to enhance anemia treatment...

Venture round
51-200 employees
Biopharma, Biotechnology
Edge Therapeutics, Inc. vs
VectivBio
VectivBio Switzerland

Biotech company develops treatments for severe rare diseases, aims to become global leader with pati...

Acquired
57 employees
Biotechnology, Health Care
Edge Therapeutics, Inc. vs
Kenai Therapeutics
Kenai Therapeutics United States

Pioneering next generation approaches to cure neurological conditions

Series A
39 employees
Biotechnology, Health Care
View all alternatives

FAQ About Edge Therapeutics, Inc.

Pioneering novel therapies to dramatically improve outcomes for life-threatening neurological conditions.
Edge Therapeutics, Inc. was founded in 2009.
Edge Therapeutics, Inc. is headquartered in United States.
Edge Therapeutics, Inc. operates in Biotechnology and Health Care. Its work centres on clinical-stage, neurological conditions, therapy and acute treatment.
Edge Therapeutics, Inc. has approximately 4 employees.
Edge Therapeutics, Inc. has completed 9 funding rounds, raising a total of $101.47M. The latest funding stage is Series C.
Top alternatives and competitors to Edge Therapeutics, Inc. include Affymax, VectivBio, Kenai Therapeutics, Biscayne Neurotherapeutics Inc, Lineage Cell Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Edge Therapeutics, Inc. and Affymax are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Edge Therapeutics, Inc., https://bouncewatch.com/company/edge-therapeutics, updated 24 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout